Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 07 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 131 Beijing 124 Shanghai 86 Changsha 72 Fuzhou 59
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca13 Sun Yat-sen University12 Merck Sharp & Dohme LLC8 Sichuan Baili Pharmaceutical Co., Ltd.8 Guangdong Association of Clinical Trials5
Site location
Guangzhou131 Beijing124 Shanghai86 Changsha72 Fuzhou59
All 110 locations
Target enrolment
to

Trials with a site in Guangzhou

131 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
660
Guangzhou
2026-10-30
Recruiting
Hoffmann-La Roche
Phase 3
400
Guangzhou
2026-10-06
Recruiting
Bristol-Myers Squibb
Phase 3
850
Beijing, Chongqing, Fuzhou, Dongguan Shi, Guangzhou, Jiangmen, Zhongshan, Guilin
2026-09-08
Not yet open
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
36
Guangzhou
2026-09
Recruiting
Guangdong Association of Clinical Trials
Phase 2
32
Guangzhou, Wuhan
2026-08-28
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
150
Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Guilin, Nanning
2026-07-15
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1/2
294
Guangzhou, Harbin, Zhengzhou, Chengdu
2026-07-10
Not yet open
Sun Yat-sen University
Phase 2
30
Guangzhou
2026-07-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Hefei, Beijing, Xiamen, Guangzhou, Guilin, Nanning, Shijiazhuang, Wuhan
2026-06-18
Recruiting
AstraZeneca
Not applicable
1,000
Anyang, Baoding, Beijing, Cangzhou, Changzhi, Chengdu, Fuzhou, Guangzhou
2026-06-02
Recruiting
AstraZeneca
Phase 4
100
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2026-05-26
Recruiting
RemeGen Co., Ltd.
Phase 3
574
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Dongguan, Guangzhou
2026-04-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Hshijiazhuang, Wuhan, Changsha
2026-03-18
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 2
40
Guangzhou
2026-03-11
Recruiting
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2
45
Guangzhou, Zhengzhou, Chengdu
2026-02-26
Recruiting
Shanghai Henlius Biotech
Phase 2
120
Hefei, Fu'zhou, Guangzhou, Nanning, Cangzhou, Harbin, Xinxiang, Wuha
2026-02-05
Recruiting
Boehringer Ingelheim
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan
2026-01-16
Recruiting
Electro-Acupuncture in Lung cancER : EALER Study
NCT07337096Non Small Cell Lung Cancer, Accupuncture, PD-1 Inhibitors
Guangzhou University of Traditional Chinese Medicine
Not applicable
424
Guangzhou, Nanjing
2026-01-15
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Jiangmen, Nanning
2026-01-06
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Shantou
2025-12-17
Recruiting
Guangdong Association of Clinical Trials
Phase 2
120
Guangzhou, Meizhou, Shantou, Shenzhen
2025-12-15
Recruiting
AbbVie
Phase 2/3
490
Guangzhou, Nanchang, Shanghai, Ürümqi
2025-12-10
Recruiting
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Phase 3
360
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-12-01
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2
300
Guangzhou
2025-11-24
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
33
Guangzhou
2025-11-11
Active, closed
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
582
Guangzhou
2025-10-30
Recruiting
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
NCT07208773Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer
DrugsTam-Peli·Ivonescimab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
260
Guangzhou
2025-10-29
Recruiting
Hoffmann-La Roche
Phase 3
600
Hefei, Nanchang, Hangzhou, Beijing, Bengbu, Changsha, Chengdu, Guangzhou
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-10-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Hefei, Beijing, Fujian, Fuzhou, Guangzhou, Nanning, Jiamusi, Zhengzhou
2025-10-08
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 2
86
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2025-09-22
Recruiting
BioNTech SE
Phase 1/2
880
Baoding, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2025-09-22
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 3
400
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Gannan, Nanchang
2025-09-10
Not yet open
Akeso
Phase 2
60
Guangzhou
2025-09-05
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
414
Hefei, Fuzhou, Guangzhou, Meizhou, Nanning, Baoding, Harbin, Anyang
2025-09-02
Recruiting
AstraZeneca
Phase 2
278
Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei
2025-08-07
Recruiting
Dizal Pharmaceuticals
Phase 1/2
220
Beijing, Guangzhou, Harbin, Changsha, Nanjing, Shengyang, Jinan, Shanghai
2025-07-30
Recruiting
Pfizer
Phase 3
714
Hefei, Beijing, Fuzhou, Guangzhou, Huizhou, Nanning, Harbin, Luoyang
2025-07-23
Recruiting
Beijing Pearl Biotechnology Limited Liability Company
Phase 3
300
Beijing, Guangzhou
2025-07-07
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Guangzhou, Shenyang, Chengdu, Hangzhou
2025-07-01
Not yet open
Betta Pharmaceuticals Co., Ltd.
Phase 2
100
Hefei, Lanzhou, Dongguan, Foshan, Guangzhou, Baoding, Harbin, Zhengzhou
2025-03-31
Active, closed
RemeGen Co., Ltd.
Phase 1
121
Beijing, Foshan, Guangzhou, Jiangmen, Gulin, Nanning, Harbin, Hanyang
2025-03-13
Recruiting
Summit Therapeutics
Phase 3
780
Fuyang, Beijing, Fuzhou, Guangzhou, Nanning, Guiyang, Haikou, Harbin
2025-02-27
Recruiting
Daiichi Sankyo
Observational
150
Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei
2025-02-21
Active, closed
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
498
Guangzhou
2024-11-29
Recruiting
Nuvation Bio Inc.
Phase 3
194
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Zhengzhou
2024-11-27
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
420
Guangzhou
2024-11-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou
2024-11-21
Recruiting
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2024-11-18
Not yet open
Guangdong Association of Clinical Trials
Not applicable
342
Dongguan, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2024-11
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Guangzhou, Huizhou, Liuzhou
2024-10-07
Active, closed
Amgen
Phase 1
49
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changchun, Chengdu, Beijing
2024-09-17
Recruiting
Guangzhou Medical University
Observational
1,000
Guangzhou
2024-09-01
Recruiting
BeBetter Med Inc
Phase 2
30
Guangzhou
2024-08-28
Active, closed
Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot Study
NCT06461338Non-small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
Guangzhou University of Traditional Chinese Medicine
Not applicable
60
Guangzhou, Nanjing
2024-08-15
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 2
120
Guangzhou
2024-08-07
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
270
Fuzhou, Foshan, Guangzhou, Jiangmen, Shenzhen, Nanning, Zunyi, Harbin
2024-08-06
Recruiting
Sun Yat-sen University
Phase 3
490
Guangzhou
2024-08-01
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
570
Guangzhou
2024-06-25
Recruiting
Guangdong Provincial People's Hospital
Phase 2
25
Guangzhou
2024-06-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Jiamusi
2024-05-24
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
432
Guangzhou
2024-05-22
Recruiting
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
NCT06542159Adaptive Radiotherapy, Stereotactic Body Radiotherapy, Non-small Cell Lung Cancer, Lung Oligometastases
Sun Yat-sen University
Phase 2
130
Guangzhou
2024-05-22
Recruiting
AstraZeneca
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2024-04-29
Recruiting
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
NCT06403735Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 1
250
Guangzhou, Harbin, Nanchang, Shanghai, Kunming
2024-04-25
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
78
Guangzhou
2024-04-24
Recruiting
AstraZeneca
Phase 3
675
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-04-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Suzhou
2024-04-03
Active, closed
Guangdong Provincial People's Hospital
Phase 2
32
Guangzhou
2024-04-01
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
522
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Zhanjiang
2024-03-28
Recruiting
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
NCT06582940MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer, Brain Metastasis
Sun Yat-sen University
Phase 2
168
Guangzhou
2024-03-01
Not yet open
Myeloprotection With Trilaciclib in Pan-cancer Population
NCT06297811Non-Small Cell Lung Cancer, Breast Cancer, Endometrial Cancer, Cervical Cancer
DrugsTrilaciclib·Paclitaxel·Carboplatin
Sun Yat-sen University
Phase 2
132
Guangzhou
2024-03-01
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
121
Chongqing, Fuzhou, Guangzhou, Liuzhou, Luoyang, Zhengzhou, Wuhan, Changsha
2024-01-29
Recruiting
Teligene US
Phase 2
66
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jinan
2023-12-27
Active, closed
Shenzhen TargetRx Co., Ltd.
Phase 3
321
Guangzhou
2023-12-14
By invitation
Avistone Biotechnology Co., Ltd.
Phase 3
327
Guangzhou
2023-12-01
Active, closed
Summit Therapeutics
Phase 3
1,600
Yangzhou, Tongzhou, Fuzhou, Lanzhou, Guangzhou, Nanning, Haikou, Shijiazhuang
2023-10-26
Recruiting
Beijing Pearl Biotechnology Limited Liability Company
Phase 3
136
Guangzhou
2023-10-16
Active, closed
Sun Yat-sen University
Not applicable
620
Beijing, Fuzhou, Lanzhou, Dongguan, Foshan, Guangzhou, Wuhan, Nanjing
2023-08-16
Recruiting
The First Affiliated Hospital of Guangzhou Medical University
Phase 1/2
29
Guangzhou
2023-07-26
Active, closed
OncoC4, Inc.
Phase 3
630
Hefei, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Nanning, Haikou
2023-06-28
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
376
Guangzhou
2023-06-26
Active, closed
Shanghai Chest Hospital
Observational
305
Hefei, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Jinan, Shanghai
2023-05-08
Active, closed
Klus Pharma Inc.
Phase 2
356
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-04-19
Active, closed
AstraZeneca
Phase 2
51
Beijing, Chengdu, Fuzhou, Guangzhou, Kunming, Ningbo, Shijiazhuang, Suzhou
2023-02-09
Active, closed
Shenzhen TargetRx Co., Ltd.
Phase 2
164
Guangzhou
2023-01-18
Active, closed
Dizal Pharmaceuticals
Phase 3
324
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-12-13
Recruiting
Henan Genuine Biotech Co., Ltd.
Phase 1/2
153
Beijing, Guangzhou, Zhengzhou
2022-10-31
Active, closed
Gilead Sciences
Phase 3
1,021
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Hangzhou, Jiangxi, Jinan
2022-10-12
Recruiting
Teligene US
Phase 2
128
Bengbu, Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2022-09-01
Active, closed
Sun Yat-sen University
Phase 2
47
Guangzhou
2022-08-01
Recruiting
Guangdong Association of Clinical Trials
Observational
180
Foshan, Guangzhou, Shantou, Zhongshan
2022-08-01
Recruiting
Guangzhou University of Traditional Chinese Medicine
Not applicable
82
Guangzhou
2022-06-15
Active, closed
Pierre Fabre Medicament
Phase 2
63
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-06-02
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
110
Guangzhou
2022-05-20
Recruiting
Sun Yat-sen University
Phase 2
280
Changchun, Chengdu, Dongguan, Dongyang, Foshan, Guangzhou, Hangzhou, Jiangmen
2022-05-06
Recruiting
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
NCT06706713Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
DrugBEBT-109
BeBetter Med Inc
Phase 2
200
Guangzhou, Changsha
2022-04-15
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
DrugsJAB-3312·Glecirasib
Allist Pharmaceuticals, Inc.
Phase 1/2
240
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou
2022-04-14
Recruiting
AbbVie
Phase 3
768
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2022-03-25
Active, closed
AstraZeneca
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-02-21
Active, closed
AstraZeneca
Phase 3
1,051
Anyang, Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Hefei, Kunming
2022-02-07
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
14
Guangzhou, Guilin, Guangdong
2022-01-06
Active, closed
Li Zhang, MD
Phase 2
106
Guangzhou
2022-01-06
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
DrugLorlatinib
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
69
Chongqing, Guangzhou, Guilin, Jinan, Taizhou
2021-12-07
Recruiting
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
NCT05024214Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
DrugsEnvafolimab·Sunitinib·Lenvatinib
3D Medicines (Sichuan) Co., Ltd.
Phase 1/2
170
Bengbu, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Zhuhai, Haerbin
2021-11-15
Active, closed
AstraZeneca
Phase 3
98
Beijing, Ganzhou, Guangzhou, Jinan, Shenyang, Tianjin, Zhengzhou
2021-09-12
Active, closed
Hutchmed
Phase 3
412
Guangzhou
2021-09-06
Recruiting
Sun Yat-sen University
Phase 2
30
Guangzhou
2021-08-13
Active, closed
Dizal Pharmaceuticals
Phase 2
104
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2021-07-19
Recruiting
Boehringer Ingelheim
Phase 1
554
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai
2021-07-02
Active, closed
Sun Yat-sen University
Observational
231
Guangzhou
2021-06-05
Recruiting
Sun Yat-sen University
Phase 3
524
Guangzhou
2021-06-01
Active, closed
Shenzhen TargetRx Co., Ltd.
Phase 1
198
Guangzhou
2021-04-23
Active, closed
AstraZeneca
Phase 3
358
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang
2020-12-16
Active, closed
Sun Yat-sen University
Not applicable
1,124
Chongqing, Lanzhou, Guangzhou, Shenzhen, Guilin, Zhengzhou, Wuhan, Nanjing
2020-08-25
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
537
Beijing, Guangzhou, Zhengzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2020-07-14
Active, closed
BeiGene
Phase 3
453
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Jiangmen, Shantou
2020-05-29
Active, closed
Eli Lilly and Company
Phase 3
261
Beijing, Guangzhou, Harbin, Wuhan, Changsha, Changzhou, Changchun, Shanghai
2020-02-17
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Early Phase 1
11
Guangzhou
2019-09-01
Active, closed
Guangdong Association of Clinical Trials
Phase 2
316
Guangzhou
2019-08-08
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2019-07-09
Active, closed
AstraZeneca
Phase 3
587
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2019-07-02
Recruiting
APG-2449 in Patients With Advanced Solid Tumors
NCT03917043Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
DrugAPG -2449
Ascentage Pharma Group Inc.
Phase 1
165
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou
2019-05-27
Active, closed
AstraZeneca
Phase 3
825
Beijing, Changsha, Changzhou, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2018-12-06
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Not applicable
100
Guangzhou
2018-11-01
Active, closed
AbbVie
Phase 2
270
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin, Zhengzhou
2018-10-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Tianjin, Beijing, Guangzhou, Changsha, Shanghai, Xi’an, Hangzhou, Ningbo
2018-04-24
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2017-09-22
Active, closed
Xcovery Holdings, Inc.
Phase 3
290
Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanjing
2016-06
Rows per page Showing 1–131 of 131
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 07 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 131 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

76 of the 131 studies on this page are recruiting new participants as of the 07 Nov 2026, 03:17 UTC sync. A further 7 have not yet opened recruitment, 47 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 131 studies
PhaseStudiesRecruitingShare
Phase 3533040.5%
Phase 2402330.5%
Phase 1/21198.4%
Not applicable846.1%
Phase 1745.3%
Observational634.6%
Phase 2/3312.3%
Phase 4211.5%
Early Phase 1110.8%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
AstraZeneca136
Sun Yat-sen University126
Merck Sharp & Dohme LLC86
Sichuan Baili Pharmaceutical Co., Ltd.83
Guangdong Association of Clinical Trials53
Avistone Biotechnology Co., Ltd.43
Dizal Pharmaceuticals41
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.42
AbbVie32
Guangzhou University of Traditional Chinese Medicine32
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.